Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03702725 · ClinicalTrials.gov registry record · Phase 1
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, sponsored by Alliance Foundation Trials.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 5
- Study locations
NCT03702725 is a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma that has completed, run by Alliance Foundation Trials. The registered enrollment target is 14 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT03702725, a Phase 1 study of Multiple Myeloma and Refractory Multiple Myeloma, has completed, sponsored by Alliance Foundation Trials.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Ibrutinib
Study Locations (5)
Illinois
- Loyola University Medical Center - Maywood
Massachusetts
- Dana Farber Cancer Institute - Boston
North Carolina
- Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Ohio
- The Ohio State University Wexner Medical Center/James Cancer Hospital - Columbus
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2024-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03702725
The ClinicalTrials.gov registry entry for NCT03702725 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (97% lower). The listed sponsor is Alliance Foundation Trials, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT03702725 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT03702725 about?
NCT03702725 is a clinical study titled "Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma". This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.
What is the current status of trial NCT03702725?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2019-08-29. Estimated completion is 2024-10-04.
What conditions does trial NCT03702725 study?
This clinical trial studies the following conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse.
What interventions are being tested in trial NCT03702725?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT03702725?
This trial is sponsored by Alliance Foundation Trials, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03702725 being conducted?
This trial has 5 study locations across Illinois, Massachusetts, North Carolina, Ohio, Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.